SRPIN340 is primarily used as a selective inhibitor of serine-arginine protein kinases (SRPKs), particularly SRPK1 and SRPK2. It is widely applied in biomedical research to modulate alternative splicing of pre-mRNA by interfering with the phosphorylation of SR splicing factors. This makes it a valuable tool in studying diseases where splicing dysregulation plays a key role, such as cancer, retinal disorders, and viral infections. In oncology research, SRPIN340 has shown potential in reducing tumor growth and angiogenesis, especially in models of pancreatic and prostate cancers, by correcting aberrant splicing events that contribute to malignancy. It has also been investigated for its anti-angiogenic effects in models of diabetic retinopathy, where inhibition of SRPK1 helps restore normal vascular function. Additionally, SRPIN340 is used to probe the role of SRPK signaling in inflammation and viral replication, including studies on dengue and hepatitis C viruses, where host cell splicing mechanisms are exploited by the virus. Its ability to cross cell membranes makes it suitable for cell-based assays and in vivo studies, supporting its use in preclinical research to validate SRPKs as therapeutic targets.